Premium
Warfarin Pharmacogenetics: To Genotype or Not to Genotype, That Is the Question
Author(s) -
Cavallari L H,
Nutescu E A
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2014.78
Subject(s) - warfarin , pharmacogenetics , dosing , clinical pharmacology , vkorc1 , medicine , genotype , cyp2c9 , clinical trial , pharmacology , biology , atrial fibrillation , genetics , cytochrome p450 , metabolism , gene
Genotype is well recognized to influence the dose of warfarin necessary for therapeutic anticoagulation. Recent randomized controlled trials evaluating the clinical utility of genotype‐guided warfarin dosing have produced varying results. We review the design and results of the recent clinical trials, assess the impact of their findings on warfarin dosing, and examine unanswered questions related to clinical implementation of warfarin pharmacogenetics. Clinical Pharmacology & Therapeutics (2014); 96 1, 22–24. doi: 10.1038/clpt.2014.78